^(125)I粒子植入联合吉西他滨治疗老年非小细胞肺癌

Radioactive seed ^(125)Ⅰ implantation plus gemcitabine in the treatment for elderly non-small cell lung cancer

目的:探讨125I放射性粒子植入联合吉西他滨(GEM)治疗老年非小细胞肺癌(NSCLC)的临床价值。方法:将61例老年NSCLC患者分成两组,治疗组(n=31)采用GEM化疗联合CT引导下经皮肺穿刺肿瘤内植入125I粒子,对照组(n=30)采用GEM单药化疗。结果:治疗组CR 6例,PR 11例,SD 10例,PD 4例,总有效率为54.84%(17/31),疾病控制率为87.10%(27/31),中位生存期为12.0个月;对照组CR 0例,PR 5例,SD 14例,PD 11例,总有效率为16.67%(5/30),疾病控制率为63.33%(19/30),中位生存期为9.0个月。差异有统计学意义(P<0.05)。治疗过程中两组的不良反应发生率差异无显著性(P>0.05)。结论:吉西他滨化疗联合125I放射性粒子肿瘤内植入治疗老年NSCLC疗效好,创伤小,不良反应发生率低。

Objective：To investigate the clinical value of radioactive seed 125I implantation combined with gemcitabine（GEM） in treatment for elderly non-small cell lung cancer（NSCLC）.Methods：Sixtyong NSCLC patients were divided into two groups.The observation group（n=31） was treated under CT guided radioactive seed125I implantation combined with GEM.The control group（n=30） was treated with regular GEM regimen only.Results：The observation group revealed CR in 6,PR in 11,SD in 10,PD in 4 cases and the total effective rate reached 54.84% with total control rate as 87.10%.The median survival time was 12.0 months.The control group showed tumors under controlling as CR in 0,PR in 5,SD in 14,PD in 11 cases,the total effective rate was16.67% and the total control rate was 63.33%.The median survival time was 9.0 months.There was a significant difference（P0.05） between two groups.The adverse events of two groups had no significant difference（P0.05）.Conclusions：CT guided radioactive seed 125I implantation combined with GEM in treatment for the elderly patients with non-small cell lung cancer（NSCLC） has fine clinical efficiency with minimal damage and few complications.